|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||38.26 / 52.64|
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.
Zoetis is not averse to a little noise as investors, analysts take notice.
Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.
Zoetis (ZTS) stock is a smart buy for investors as a result of its growing pet business, Aureus Asset Management CEO Karen Firestone said on CNBC.
Cramer says McCormick is up too much and he's not chasing Clayton Williams Energy.
There are too many companies in just about every sector of this market, Cramer says.
Paul Herendeen, former CFO of Zoetis, will assume those duties as his new employer eyes divestitures.
Zoetis (ZTS) announced that Glenn David would be its new CFO effective immediately.
Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.
Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer
Cramer said investors should be cheering the reported arrival of CFO Paul Herendeen at Valeant.
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
A potential blockbuster drug deal is reportedly in the works.
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the...
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.
TheStreet's Jim Cramer says the humanization of pets is a growing investment opportunity.
The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.
Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices, a pioneer in developing and manufacturing microfluidic "lab on a chip" diagnostic analyzers and tests for...
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
UBS' Stephen Freedman and Mizuho's Steven Ricchiuto explained why investors should not be concerned about the recent downturn of the market on CNBC today.
Zoetis (ZTS) stock was trading higher pre-market as it boosted its outlook after reporting better-than-expected earnings and revenue for the second quarter.
Trade-Ideas LLC identified Zoetis (ZTS) as a pre-market leader candidate
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2016 and increased its revenue and adjusted net income guidance for full year 2016.
Zoetis (ZTS) is expected to post 2016 second-quarter results before tomorrow's opening bell.
Earnings season is still in full swing and Cramer wants you to know which stocks he'll be watching and how to use his knowledge to be a better investor.